DICE Therapeutics, Inc.

SEC insider activity covers quarterly filings through June 30, 2026. Later filings are not included. Reported roles do not establish current employment or current holdings. SEC filing documents, sections and filing-text search cover filings dated January 1, 2000 onward. Earlier filings are deferred until after launch.

organization

SEC Insider

$238.1M

184 transactions

Summary

DICE Therapeutics, Inc. is an organization.

Recent Insider Transactions

As filed, including amendments; not net cash flow or current holdings. Joint reports count once. Totals cover known values only.

Buys: $116.0MSales: $122.1M20 insiders

Date	Insider	Type	Value
2023-08-09	Joint reporting: RA Capital Healthcare Fund LP; RA CAPITAL MANAGEMENT, L.P.; Kolchinsky Peter; Shah Rajeev M.; RA Capital Nexus Fund II, L.P.	D	—
2023-08-09	Joint reporting: RA Capital Healthcare Fund LP; RA CAPITAL MANAGEMENT, L.P.; Kolchinsky Peter; Shah Rajeev M.; RA Capital Nexus Fund II, L.P.	U	—
2023-08-09	Joint reporting: RA Capital Healthcare Fund LP; RA CAPITAL MANAGEMENT, L.P.; Kolchinsky Peter; Shah Rajeev M.; RA Capital Nexus Fund II, L.P.	U	—
2023-08-09	Bowers Lisa	D	—
2023-08-09	Doyle Mittie	D	—
2023-08-09	Jacobsen John R.(CSO)	D	—
2023-08-09	Jacobsen John R.(CSO)	D	—
2023-08-09	Jacobsen John R.(CSO)	D	—
2023-08-09	Jacobsen John R.(CSO)	D	—
2023-08-09	Jacobsen John R.(CSO)	D	—
2023-08-09	Jacobsen John R.(CSO)	D	—
2023-08-09	Jacobsen John R.(CSO)	D	—
2023-08-09	Jacobsen John R.(CSO)	D	—
2023-08-09	Jacobsen John R.(CSO)	D	—
2023-08-09	Jacobsen John R.(CSO)	D	—
2023-08-09	Jacobsen John R.(CSO)	D	—
2023-08-09	Jacobsen John R.(CSO)	D	—
2023-08-09	Jacobsen John R.(CSO)	D	—
2023-08-09	Jacobsen John R.(CSO)	D	—
2023-08-09	Judice Kevin(CEO)	D	—

SEC filings: SEC EDGAR

Activity data: SEC EDGAR

DICE Therapeutics, Inc. — Contributions, Lobbying & Contracts | Poliscope